A Phase 1 Open-Label Single-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of OP-101 (Dendrimer N-Acetyl-Cysteine) After Intravenous Administration in Healthy Volunteers

Trial Profile

A Phase 1 Open-Label Single-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of OP-101 (Dendrimer N-Acetyl-Cysteine) After Intravenous Administration in Healthy Volunteers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Apr 2018

At a glance

  • Drugs OP-101 (Primary)
  • Indications Adrenoleucodystrophy; Neurological disorders
  • Focus Adverse reactions
  • Sponsors Orpheris
  • Most Recent Events

    • 16 Apr 2018 Status changed from planning to recruiting.
    • 05 Dec 2017 New trial record
    • 27 Nov 2017 According to an Orpheris media release, this trial is anticipated to complete in Q1 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top